종양학 기반 In-Vivo CRO 시장 : 서비스, 적응증, 최종사용자별 - 세계 예측(2025-2030년)

The Oncology Based In-Vivo CRO Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.41 billion in 2024, and is projected to grow at a CAGR of 11.34%, to USD 2.70 billion by 2030.

The scope of oncology-based in-vivo CROs (Contract Research Organizations) involves providing a wide range of services for preclinical studies, focusing on the comprehensive assessment of novel cancer therapies in living organisms. Precisely, these CROs conduct studies that evaluate the efficacy, safety, and pharmacokinetics of oncology drugs, facilitating a critical step in drug development. Their necessity stems from the increasing demand for personalized medicine and the relentless pursuit of effective cancer treatments. Applications are versatile, including drug discovery, translational research, and regulatory submissions, serving end-uses in pharmaceutical companies, research institutions, and biotech firms. Key growth factors driving this market include the rising incidence of cancer worldwide, growing investments in oncology research, and technological advancements in animal modeling.

Latest opportunities are emerging with the integration of artificial intelligence and big data analytics, which enhance the predictive modeling of clinical outcomes and streamline drug development processes. Leveraging collaborations with academia and emerging biotech for innovative, cost-effective study designs is also a promising avenue. However, the market faces challenges such as stringent regulatory requirements and ethical concerns related to animal testing, which can delay and complicate study processes. Additionally, competition from in-vitro models and reluctance from stakeholders due to cost constraints are substantial barriers.

Market innovations could focus on developing more predictive and humane in-vivo models, incorporating digital biomarkers, and enhancing the precision of data gathered from animal studies. Companies should consider investing in technologies that improve the reproducibility of results and reduce attrition rates. The nature of this market is dynamic, with a strong emphasis on the adaptability to new scientific advancements and regulatory changes. Businesses aiming for growth should prioritize forming strategic partnerships, investing in personalized study models, and ensuring compliance with evolving global standards to secure a competitive advantage in this rapidly evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Based In-Vivo CRO Market

The Oncology Based In-Vivo CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of cancer and need for effective drug discovery
  • Rising need for optimized and efficient oncology clinical trial activities
  • Government initiatives encouraging personalized medicine
• Market Restraints
  • Concerns associated with data security and privacy
• Market Opportunities
  • Advancements in oncology-based in-vivo technologies with data analytics and AI
  • Expansion of oncology CRO services for biomarker development
• Market Challenges
  • Limitations of regulatory compliance of oncology trials

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Based In-Vivo CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Based In-Vivo CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Based In-Vivo CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Based In-Vivo CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Based In-Vivo CRO Market

A detailed market share analysis in the Oncology Based In-Vivo CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Based In-Vivo CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Based In-Vivo CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Based In-Vivo CRO Market

A strategic analysis of the Oncology Based In-Vivo CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Based In-Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Altogen Labs, Cellvax, SAS, Charles River Laboratory, Crown Bioscience, Cyagen Biosciences, Evotec SE, Explicyte by Immusmol SAS Company, Icon PLC, Imavita, IVRS AB, Laboratory Corporation of America Holdings, Melior Discovery, Noble Life Sciences, Pharmaron, Pharmatest Services, Reaction Biology by Copeba, Redoxis AB, Taconic Biosciences, Inc., The Jackson Laboratory, and XenTech.

Market Segmentation & Coverage

This research report categorizes the Oncology Based In-Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Services, market is studied across Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies, and Preclinical Studies.
• Based on Indication, market is studied across Hematological Malignancies, Rare Cancer, and Solid Tumor.
• Based on End-User, market is studied across Academic & Research Institutes, Biotechnology Companies, and Pharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of cancer and need for effective drug discovery
    • 5.1.1.2. Rising need for optimized and efficient oncology clinical trial activities
    • 5.1.1.3. Government initiatives encouraging personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with data security and privacy
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in oncology-based in-vivo technologies with data analytics and AI
    • 5.1.3.2. Expansion of oncology CRO services for biomarker development
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations of regulatory compliance of oncology trials
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncology Based In-Vivo CRO Market, by Services

• 6.1. Introduction
• 6.2. Biomarker Development
• 6.3. Clinical Trial Management
• 6.4. Pharmacokinetics Studies
• 6.5. Preclinical Studies

7. Oncology Based In-Vivo CRO Market, by Indication

• 7.1. Introduction
• 7.2. Hematological Malignancies
• 7.3. Rare Cancer
• 7.4. Solid Tumor

8. Oncology Based In-Vivo CRO Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Biotechnology Companies
• 8.4. Pharmaceutical Companies

9. Americas Oncology Based In-Vivo CRO Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Oncology Based In-Vivo CRO Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Based In-Vivo CRO Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Altogen Labs
• 2. Cellvax, SAS
• 3. Charles River Laboratory
• 4. Crown Bioscience
• 5. Cyagen Biosciences
• 6. Evotec SE
• 7. Explicyte by Immusmol SAS Company
• 8. Icon PLC
• 9. Imavita
• 10. IVRS AB
• 11. Laboratory Corporation of America Holdings
• 12. Melior Discovery
• 13. Noble Life Sciences
• 14. Pharmaron
• 15. Pharmatest Services
• 16. Reaction Biology by Copeba
• 17. Redoxis AB
• 18. Taconic Biosciences, Inc.
• 19. The Jackson Laboratory
• 20. XenTech